Prostate Cancer Metastatic Disease Clinical Trials

10 recruiting

Prostate Cancer Metastatic Disease Trials at a Glance

10 actively recruiting trials for prostate cancer metastatic disease are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Boston, Carmel, and Chicago. Lead sponsors running prostate cancer metastatic disease studies include Halda Therapeutics OpCo, Inc., Maastricht Radiation Oncology, and Clinton Bahler.

Browse prostate cancer metastatic disease trials by phase

Treatments under study

About Prostate Cancer Metastatic Disease Clinical Trials

Looking for clinical trials for Prostate Cancer Metastatic Disease? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostate Cancer Metastatic Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostate Cancer Metastatic Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

Prostate CancerAdvanced Prostate CancerProstate Cancer Metastatic Disease+1 more
Maastricht Radiation Oncology600 enrolled3 locationsNCT07004582
Recruiting
Phase 2

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Prostate Cancer Metastatic Disease
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine192 enrolled1 locationNCT06832774
Recruiting
Phase 2

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Prostate CancerProstate CarcinomaProstate Neoplasm+12 more
Shehzad Basaria, M.D.60 enrolled1 locationNCT06957691
Recruiting
Phase 2

Using FAPI PET/MRI to Evaluate Prostate Cancer

Prostate CancersProstate Cancer Metastatic Disease
University of Wisconsin, Madison30 enrolled1 locationNCT06675357
Recruiting
Phase 2

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

Prostate Cancer SurgeryProstate Cancer Metastatic Disease
Clinton Bahler22 enrolled3 locationsNCT06849544
Recruiting
Not Applicable

PSMA PET for Surveillance After Focal Therapy

Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic DiseaseProstate Cancer (Diagnosis)
University of Chicago62 enrolled1 locationNCT07115914
Recruiting

Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer

Prostate Cancer Metastatic Disease
University Hospital, Grenoble130 enrolled1 locationNCT06828263
Recruiting
Not Applicable

Role of Race in Nutritional Approach in Men on ADT

Prostate Cancer Metastatic Disease
University of California, Los Angeles70 enrolled2 locationsNCT06682390
Recruiting
Phase 1Phase 2

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Disease
Halda Therapeutics OpCo, Inc.33 enrolled11 locationsNCT06800313
Recruiting
Phase 2

Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

Prostate Cancer Metastatic Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School144 enrolled1 locationNCT06992232